Characteristic | n (%) | Characteristic | n (%) |
---|---|---|---|
Source of data | Guidance for a specific condition | ||
Grey literature | 65 (81%) | Yes | 22 (28%) |
Peer-reviewed | 15 (19%) | No | 58 (72%) |
Patients and public partners’ involvement in creation of the guidance | Guidance for a specific context | ||
Yes | 14 (18%) | Yes | 30 (38%) |
No | 66 (82%) | No | 50 (62%) |
Country of publishing | Year of publication | ||
United Kingdom | 24 (30%) | 2022 | 27 (34%) |
Canada | 19 (24%) | 2021 | 13 (17%) |
United States | 19 (24%) | 2020 | 5 (7%) |
Norway | 4 (5%) | 2019 | 5 (7%) |
India | 2 (2%) | 2018 | 6 (7%) |
Australia | 1 (1%) | 2017 | 8 (10%) |
Belgium | 2(2%) | 2016 | 2 (2%) |
Germany | 1 (1%) | 2015 | 5(6%) |
Iran | 1 (1%) | 2014 | 6 (7%) |
Japan | 1 (1%) | 2013 | 2 (2%) |
Mixed | 6 (7%) | 2012 | 1 (1%) |
Objective of guidance* | Guidance target audience(s) | ||
LS characteristics | 79 (99%) | (A) Researchers | 76 (95%) |
Specific writing process | 10 (13%) | (B) Others (patient and public partners, | 4 (5%) |
Both | 9 (11%) | policymakers, funders, unspecified) | Â |